Introduction
Cervical cancer remains a significant global health concern, with early-stage detection offering the potential for curative treatment. Traditional surgical management involves hysterectomy combined with pelvic lymphadenectomy to evaluate lymph node status, which guides post-operative therapy and staging. However, lymphadenectomy is associated with substantial morbidity, including lymphocysts, lymphedema, and nerve injury. The advent of sentinel lymph-node (SLN) biopsy has revolutionized staging in several cancers, notably breast cancer and melanoma, and its application in cervical cancer has been under active investigation.
This article critically examines the recent multicenter, randomized noninferiority trial comparing sentinel-lymph-node biopsy alone versus conventional lymphadenectomy in early-stage cervical cancer. The study aims to determine whether less invasive nodal assessment can maintain oncologic safety while reducing surgical morbidity.
